Welcome to the e-CCO Library!

search
Search by: 
Year: Category:
OP021: Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Brierley1*, C. Castilla-Llorente2, M. Labopin3, M. Badoglio3, M. Rovira4, E. Ricart5, D. Dierickx6, S. Vermeire7, P. Hasselblatt8, J. Finke9, F. Onida10, A. Cassinotti11, J. Satsangi12, M. Kazmi13, A. López-Sanromán14, D. Farge15, S. Travis16, C. Hawkey17, J. Snowden18

Created: Thursday, 21 February 2019, 9:14 AM
OP021: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-to-severe Crohn’s disease: results of a Phase 2b randomised placebo-controlled trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens*1, R. Pannaccione2, P. D. R. Higgins3, J.-F. Colombel3, B. G. Feagan4, M. Moscariello5, G. Chan5, P. Healey6, W. Niezychowski5, W. Wang5, A. Marren5, E. Maller5

Created: Friday, 22 February 2019, 9:49 AM
OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate- severe flares: A multi-center, randomised, double-blind, sham- controlled trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Dulai P.
Last Modified: Wednesday, 15 March 2017, 2:31 PM by ECCO Administrator
Files: 1
OP021: Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dulai P.*1,2, Buckey Jr. J.2, Raffals L.3, Swoger J.4, Claus P.3, O'Toole K.4, Ptak J.2, Gleeson M.2, Widjaja C.1, Adler J.2, Patel N.2, Skinner L.2, Haren S.3, Goldby-Reffner K.4, Thompson K.2, Knight R.1, Chang J.1, Siegel C.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP022: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohn’s disease: results of a Phase 2b randomised placebo-controlled trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. Panés*1, W. J. Sandborn2, S. Schreiber3, B. E. Sands4, S. Vermeire5, G. Chan6, M. Moscariello6, W. Wang6, W. Niezychowski6, A. Marren6, P. Healey7, E. Maller6

Created: Friday, 22 February 2019, 9:49 AM
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kalla R.
Last Modified: Wednesday, 15 March 2017, 2:30 PM by ECCO Administrator
Crohn's disease, Ulcerative colitis, Immunology
Files: 1
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kalla R.*1, Adams A.1, Vatn S.2, Bergemalm D.3, Ricanek P.4, Lindstrom J.2, Ocklind A.5, Nordberg N.5, Kennedy N.1, Ventham N.1, Vatn M.4, Söderholm J.6, Pierik M.7, Törkvist L.8, Gomollόn F.9, Jahnsen J.2, Halfvarson J.3, Satsangi J.1 IBD Character Consortium, Edinburgh, United Kingdom

Created: Wednesday, 20 February 2019, 10:36 AM
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Schreiber1*, L. Peyrin-Biroulet2, B. Boland3, P.D. Higgins4, A. Armuzzi5, J. Terdiman6, W. Zhou7, G. Alperovich8, F. Cataldi7, S. Goteti7, A.P. Lacerda7

Created: Thursday, 21 February 2019, 9:14 AM
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study
Year: 2018
Source: ECCO'18 Vienna
Authors: Schreiber Stefan
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Danese1*, B. Feagan2, W. Sandborn3, J.-F. Colombel4, S. Vermeire5, S. Jones6, K. Brennan6, J. Bornstein7

Created: Thursday, 21 February 2019, 9:14 AM
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn’s Disease (CD)
Year: 2018
Source: ECCO'18 Vienna
Authors: Danese Silvio
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP023: Comparison between newly developed narrow band imaging and panchromoendoscopy for surveillance colonoscopy in patients with ulcerative colitis: a prospective multicentre randomised controlled trial, navigator study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Watanabe*1, M. Nishishita2, F. Shimamoto3, T. Fukuchi4, M. Esaki5, Y. Okamoto5, Y. Maehata5, S. Oka6, S. Nishiyama6, S. Fujii7, F. Hirai8, T. Inoue9, N. Hida10, R. Nozaki11, T. Sakurai12, K. Takeuchi13, M. Saruta14, S. Saito15, Y. Saito16, N. Ohmiya17, H. Kashida12, S. Tanaka6, T. Matsui8, Y. Suzuki18, Y. Ajioka19, H. Tajiri20

Created: Friday, 22 February 2019, 9:49 AM
OP023: Maintenance of clinical effect in patients with moderate- to-severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Vermeire S.
Last Modified: Wednesday, 15 March 2017, 2:28 PM by ECCO Administrator
Filgotinib
Files: 1
OP023: Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, Schreiber S.2, Petryka R.3, Kuehbacher T.4, Hebuterne X.5, Roblin X.6, Klopocka M.7, Goldis A.8, Wisniewska-Jarosinska M.9, Baranovsky A.10, Sike R.11, Stoyanova K.12, Meuleners L.13, Tasset C.13, Van der Aa A.13, Harrison P.13

Created: Wednesday, 20 February 2019, 10:36 AM
OP024: Childhood-onset inflammatory bowel disease and risk of cancer – a Swedish nationwide cohort study 1964–2014
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Olén O.*1,2, Askling J.1, Frumento P.3, Sachs M.C.3, Neovius M.1, Eriksson J.1, Smedby K.E.1, Ekbom A.1, Malmborg P.1,2, Ludvigsson J.F.4,5,6,7

Created: Wednesday, 20 February 2019, 10:36 AM
OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014
Year: 2017
Source: ECCO'17 Barcelona
Authors: Olén O.
Last Modified: Wednesday, 15 March 2017, 2:27 PM by ECCO Administrator
IBD and malignancy, Lymphoma, Paediatric
Files: 1
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study
Year: 2018
Source: ECCO '18 Vienna
Authors:

G.R. D’Haens1*, W. Reinisch2, S.D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D.I. Park9, X. Hébuterne10, F. Cataldi11, A. Banerjee12, K. Gorelick13, W.J. Sandborn14

Created: Thursday, 21 February 2019, 9:14 AM
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study
Year: 2018
Source: ECCO'18 Vienna
Authors: D´Haens Geert R
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP024: Mucosal healing and dysplasia surveillance in a large referral Centre cohort of patients with Crohn’s disease and ulcerative colitis treated with vedolizumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Noman1, M. Ferrante1, R. Bisschops1, G. De Hertogh2, K. Van Den Broeck1, K. Rans1, P. Rutgeerts1, S. Vermeire1, G. Van Assche*1

Created: Friday, 22 February 2019, 9:49 AM
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Bohm1, S.V. Sagi1, M. Fischer1, S. Kadire1, G. Tran1, M. Rahal1, S. Aniwan2, J. Meserve3, A. Weiss4, G. Kochhar5, P. Shashi5, D. Faleck6, A. Winters6, S. Chablaney6, J.L. Koliani-Pace7, B. Boland3, S. Singh3, R. Hirten6, E. Shmidt6, K. Lasch8, M. Luo8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, S. Kane2, E.V. Loftus2, B.E. Sands6, W.J. Sandborn3, J.-F. Colombel6, B. Shen5, P.S. Dulai3*

Created: Thursday, 21 February 2019, 9:14 AM